Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NUVL
Nuvalent, Inc.
Healthcare | Biotechnology
No licensed closing price on file for NUVL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Nuvalent, Inc. (NASDAQ: NUVL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 03:57 UTC.
What Nuvalent, Inc. does
This is a clinical-stage biopharmaceutical company developing small-molecule cancer therapies designed to overcome limitations of existing kinase inhibitors, including drug resistance, off-target side effects, and poor brain penetration. The company's lead candidate, zidesamtinib, is being evaluated for ROS1-positive non-small cell lung cancer in the ARROS-1 trial and received FDA acceptance of a new drug application in November 2025.
Summarized from Nuvalent, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
NUVL no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.
Oxford Ledge
Search